• TG Therapeutics Inc TGTX.OQ reported quarterly adjusted earnings of 15 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of -10 cents. The mean expectation of seven analysts for the quarter was for earnings of 8 cents per share. Wall Street expected results to range from 4 cents to 13 cents per share.

• Revenue rose 146% to $108.19 million from a year ago; analysts expected $99.95 million.

• TG Therapeutics Inc's reported EPS for the quarter was 15 cents​.

• The company reported quarterly net income of $23.33 million.

• TG Therapeutics Inc shares had fallen by 0.0% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 4.9% in the last three months.​

• In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and 1 "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for TG Therapeutics Inc is $43.00

This summary was machine generated from LSEG data March 3 at 03:57 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)